Despite in vitro predictions, acquired resistance attributable to JAK2 point mutations is not widely observed in rux-treated MPN or ALL, potentially due to an insufficient selective pressure related to the low potency and selectivity of rux27. The gene discussed is JAK2; the disease is myeloproliferative neoplasm.